Search bioRxiv⌕ Search

Biology subjects

Boucharlat, A.

Publications and source records attributed to Boucharlat, A..

2 recordsLinked to original sources

Structure-guided generative design of peptides targeting the FtsQBL divisome complex inhibit Escherichia coli cell division.

The discovery of antibiotics targeting Gram-negative bacteria remains limited in part by the difficulty of pharmacologically modulating protein-protein interactions essential for bacterial physiology. The divisome complex formed by FtsQ, FtsB and FtsL represents an attractive but challenging target, as its assembly relies on {beta}-strand-mediated interface interactions within the bacterial periplasm. Here, we combined interpretable interface mapping using InDeep with hotspot-constrained RFdiffusion design to generate peptides targeting the FtsB-binding site of Escherichia coli FtsQ. The designed peptides mimic the native {beta}-augmentation interaction and selectively engage the FtsQ interface both in bacterial cells and in vitro. X-ray crystallography of one of these peptides in complex with FtsQ reveals that it accurately adopts the native binding geometry while introducing additional stabilizing interactions within a hydrophobic pocket. Complementary NMR analyses further show that optimized peptides adopt pre-organized {beta}-hairpin conformations in solution consistent with the bound state. Several of these peptides disrupt bacterial cell division and inhibit growth in an E. coli strain exhibiting increased outer membrane permeability. Together, these results establish a structurally validated framework in which predictive interface analysis and generative design can be combined to target cooperative protein-protein interfaces in bacteria and provide a foundation for the development of divisome-targeting antibacterial strategies.

microbiology↗

Intranasal delivery of a broadly neutralizing single domain antibody targeting ACE2 protects against SARS-CoV-2 infection

SARS-CoV-2 accumulates mutations over time leading to the emergence of variants, which become largely resistant to existing vaccines and spike protein-targeted antiviral treatment. Therefore, there is a need for other therapies with broad efficiency. Here, we targeted the angiotensin-converting enzyme 2 (ACE2), the major entry receptor for SARS-CoV-2. We purified three single domain heavy chain antibodies (VHHs) after immunization of an alpaca with the ectodomain of ACE2. These VHHs bound ACE2 with nanomolar affinity and specifically detected membrane-anchored ACE2. Two of them (B07 and B09) neutralized by a competitive mechanism multiple SARS-CoV-2 isolates, including Omicron variants (XBB.1.16.1; EG.5.1.3; BA.2.86.1), without impacting the proteolytic activity of the enzyme. Fusion of B07 with conventional Fc domain markedly improved its binding and neutralizing efficacy. This dimeric Fc-conjugated B07 (B07-Fc) recognized specific residues of the N-terminal helix 1 of ACE2. When administrated prophylactically and intranasally, B07-Fc induced a strong dose-dependent protection of mice expressing human ACE2 (K18-hACE2) from SARS-CoV-2 Omicron. Hamsters were weakly protected due to low binding of B07-Fc to hamster ACE2. These single domain antibodies targeting hACE2 represent potential broad-spectrum therapeutic candidates against any emerging viruses using ACE2 as a receptor. These inhalable neutralizing single domain antibodies also represent a non-invasive approach against respiratory viral infection.

microbiology↗